De novo molecular subtyping of salivary gland tissue in the context of Sjögren's syndrome heterogeneity

Clin Immunol. 2022 Dec:245:109171. doi: 10.1016/j.clim.2022.109171. Epub 2022 Nov 5.

Abstract

Understanding the mechanistic features and molecular taxonomy of diseases holds promise for the development of more effective treatments, especially for complex heterogeneous diseases. Here, we analyzed transcriptomic datasets of salivary gland tissues from patients with Sjögren's syndrome (SjS) to identify shared and divergent cellular and molecular signatures. Three molecular subtypes of SjS salivary gland tissue were identified: oxidative phosphorylation (OxPhos)-dominant (C1), weak inflammatory with type I interferon signatures (C2), and B cell receptor (BCR) signaling pathway-dominant (C3). C3 had the highest focus score. Type I helper T cells and B cells were the dominant cell types in C1 and C3 tissues, respectively. Metformin and drugs targeting PI3K, BTK, and JAKs were predicted to be effective treatments for C1 and C3 subtypes, respectively. Three subtypes of SjS salivary gland with distinct molecular signatures were identified. The results could contribute to optimal stratification of patients for more effective treatment approaches.

Keywords: Key driver gene; Molecular signature; Salivary gland; Sjögren's syndrome; Therapeutic target.

MeSH terms

  • B-Lymphocytes / metabolism
  • Humans
  • Interferon Type I* / metabolism
  • Salivary Glands / metabolism
  • Sjogren's Syndrome* / genetics
  • Sjogren's Syndrome* / metabolism
  • Transcriptome

Substances

  • Interferon Type I